These are 2007 numbers. ASX - By Stock. Notice of Investor Call and Presentation, page-3. Spot on - filled the 1. Market . Discover historical prices for IXC. , page-4. So your thesis is right on a long time time frame. 3¢. EGREcoGraf partners with VinES Energy for pioneering Battery Anode Material Facility in Vietnam. Most bio's get. Share A few weeks ago in the lead up to the Phase 2 results invex included this slide on their slide deck - 'average 42 million increase in market cap after positive Phase 2 results'. 50%. Hi Hot Copper, this will be a master thread for my daily posting of the Pharma Market Watchlist, please only keep commentary to the watchlist. ASX - By Stock. Latest Posts. 50%. ASX - Day TradingCreated with Sketch. Last updated 10. 0¢ Sentiment: Buy Disclosure: Held Bumping up this thread as $3. IXC Price at posting: 79. 64440. . Created with Sketch. IXC Valuation Report MST. $45M MC $30M Cash and a $1. STN Saturn Metals reports high-grade gold intersections and visible gold at Apollo Hill, WAInvex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical. ASX - Day Trading. . , page-2. , page-2. A promising development for IXC, a company with a current Phase III trial that is expected to finish dosing in 12 months time, We hear from a patient from the Phase II trial completed 2 years ago, with our current Phase III trial ongoing as we speak:Simon Joyner - 14th largest holder in IXC Just a background of this board of advice. 30 order I had out there for 2-3 weeks. Share Ok news not the greatest but I dont think its as bad as people gonna re-act (mainly retailers) Primary endpoint remains unchanged Protocol changes focus on reordering secondary endpoints - replacing PMD with the more. ASX - General. Forums. Mernova, a subsidiary of Melodiol Global Health (ASX:ME1), is on track to achieve its highest ever monthly sales, with revenues expected to reach A$891,944 in October 2023. . Just a matter of time really. Last updated 15. Im not expecting anything out of the ordinary apart from the fact thats its overdone and too undervalued at the stage its at. We are a team of expert financial advisers each specialising in different, yet complementary areas. ASX - Day TradingInvex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical. But the market volume was very low, which points to a lack of interest, the long horizons of biotech, lack of publicising or Notification of cessation of securities - IXC. Created with Sketch. When can we expect some update or. Most bio's get acquired on P2 readouts, if results are strong early here. LoginJoin Now. ASX - By Stock. ASX - By Stock. Invex to Present at Upcoming Tech Biotech Broker BriefingCreated with Sketch. Created with Sketch. Created with Sketch. Created with Sketch. Market . Created with Sketch. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical developmentNotice of Annual General Meeting/Proxy Form. **Close price adjusted for splits and dividend and/or capital gain distributions. Created with Sketch. Share "Online registration will open 30 minutes before the Meeting. , page-3. 147,415. ASX - Day TradingCreated with Sketch. Cold Comfort Ice Cream Company, Victoria, British Columbia. , page-20. Bumping up this thread as $3. . Sentiment for Invex Therapeutics Ltd. Forums. . , page-32. Hi All, I have decided to make an IXC broker data thread, as my PAR broker data thread was very well received. Given that IXC's Chief Scientific Officer, Alex Sinclair, is the author of IIH treatment guidelines, the introduction of an effective medication to the market would likely lead to a rapid integration of Presendin into treatment protocols. 30 to $15 in the space of 1 and half years Bios move fast when value is recognised. Australian finance news, stock quotes, currency information and blogs0. 54pm 22/11/2023 ? HotCopper has news, discussion, prices and market data on INVEX THERAPEUTICS LTD. @FullMoonFever Another chart request if you are up for it please thanks in advance, page-7. Created with Sketch. ASX - Day TradingChange in substantial holding. Interexchange Carrier, also known as IXC, is a telco that mainly provides long-distance communication services. Invex Granted Type C Meeting with FDA, page-2. I see it at perhaps $5 prior to readout. Latest Posts. Invex Files Pre-IND/Type B Meeting Request with US FDA IXC is a long term play mate, not a daytraders plaything as too illiquid. Invex Therapeutics Limited (ASX:IXC) is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Last edited by jellyroll: 27/02/23. This was roughly 50/50 between lost wages and direct medical costs. 19 Per share (Personal Estimate) vs MST Research report of $3. Notification of cessation of securities - IXC. Hi All, Having scrolled through the IXC forum for 18-24 months now, I have seen quite literally 200+ posts of charts discussing the stock price, and only. Latest Posts. . Umbrella Society is a proud Living Wage Employer! Greater Victoria's official living wage has been adjusted to $25. ASX - By Stock. . Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical development Company with issued patents and multiple orphan drug designations focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of. Release Date: 20/03/23 08:11; Summary: German Approval for IIH EVOLVE Phase 3 Clinical Trial; Price Sensitive: Yes; Download Document 195. Created with Sketch. ASX - Day TradingA new thread to put trading comments / reasoning / opinions in. , page-3. The fact it recovered and closed about the 1. ASX - General. Date of AGM and Closing Date for Director NominationsCD is on the money once again, page-195. I think IXC has the potential to do better. 0. @FullMoonFever Another chart request if you are up for it please thanks in advance, page-4. @FullMoonFever Another chart request if you are up for it please thanks in advance, page-7. 5¢ Sentiment: Buy Disclosure: Held Ive compared IXC to NEU before and believe we approx. @FullMoonFever Another chart request if you are up for it please thanks in advance, page-2. 59). Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical. 6% $DLM 50. . Charts. Market . Hi All, I have decided to make an IXC broker data thread, as my PAR broker data thread was very well received. *Close price adjusted for splits. Target our investor community with our suite of Hotcopper Advertising. Invex Therapeutics' Chief Scientific Officer, Professor Alexandra Sinclair, met with NASA's medical team. 40. IXC Price at posting: 23. Created with Sketch. Market . June 23 (Reuters) - Invex Therapeutics Ltd (IXC) : GRANTING OF ORPHAN DRUG DESIGNATION FOR EXENATIDE IN TREATMENT OF MODERATE TO SEVERE TRAUMATIC BRAIN. AdINVEX THERAPEUTICS LTD (ASX:IXC) - IXC chart, page-1 - HotCopper | ASX Share Prices, Stock Market & Share Trading Forum Forums ASX - By Stock IXC. Created with Sketch. 3¢. ASX - Day TradingApril 20 (Reuters) - Invex Therapeutics Ltd (IXC) : MINISTRY OF HEALTH APPROVAL FOR IIH EVOLVE CLINICAL TRIAL IN ISRAELInvestor Presentation, page-2. I don't mind a capital return but you have to think that a reverse take over of some sort can happen here and that IXC would have lots of choices. Join the HotCopper ASX share market forum today for free. Is it just me or has IXC gone very quiet. IXC is at base, so it’s just a matter of when it’ll leave base and start turning to the upside. IXC is at base, so it’s just a matter of when it’ll leave base and start turning to the upside. 1. Forums. 0¢ Sentiment: Buy Disclosure: Held. AX stock on Yahoo Finance. Created with. IXC Price at posting: $1. ASX - Short Term Trading. , page-2. , page-6. View daily, weekly or monthly formats back to when Invex Therapeutics Ltd stock was issued. Advertise. INVEX THERAPEUTICS LTD (ASX:IXC) - IXC chart, page-1 - HotCopper | ASX Share Prices, Stock Market & Share Trading Forum Forums ASX - By Stock IXC IXC chart IXC invex therapeutics ltd IXC chart 1 Last ralom 17,015 Posts. Information. 0¢ Sentiment: Buy Disclosure: HeldHotCopper has news, discussion, prices and market data on GENESIS MINERALS LIMITED. , page-3. Advertise on HotCopper. . How many friends and family got out after the last announcementshould have been released at the same time, page-34. 31% more bullish than other Healthcare sector stocks. Orphan drug status. Invex Granted Type C Meeting with FDAAppendix 4E and Annual Report to shareholders. pdfGreat to see initiation of research from MST today, click the link to read the full report or read the first page in post. 6B TAM that is unencumbered and a 55% peer average neurology success rate from Phase 3!IXC although only the 1 indication has already raised the sufficient cash to go all the way, they are in phase 3 trials, they have a time line and are full steam ahead. ASX - Day Trading. 76 (-1. Created with Sketch. Australia's largest stock trading and investment forum Australia's #1 stock forum Australia's #1 stock forumIXC need to hold a conference call to discuss the announcement - they need to front up. Invex Granted Key European Patent for Exenatide, page-2. Also took placement stock @$1. Discover historical prices for IXC. Created with Sketch. Appendix 4E and Annual Report, page-2. Created with Sketch. Latest Posts ForumsThis doesn't mean that IXC is doomed, just that things are more a gamble than an investment at the moment. ASX - By Stock. Forums. Read in the announcement, has changed name and he has bought more ixc, page-2. pdfGreat to see initiation of research from MST today, click the link to read the full report or read the first page in post. Posted without a title, my bad hahaI was going for something like Invex - How much is it worth, when Phase 2 results hit in March 2020?Got this from IXC by email today. Anyone had a look at this or put an application in for some stock in the IPO?Created with Sketch. Created with Sketch. IXC needs to be proactive and release a statement. . You are still able to buy a potential multi BILLION dollar company in the 50 mill MC range. Friday we moved 55% off 690k volume. Forex. Forums. Jellyroll, arkangel, CD, balkanbroker to name a few have laid out some pretty compelling thesis' on where IXC will be heading. Company has options because they have cash. Both approaches can work, but it is not wise to confuse the two. Appendix 4C - quarterlyAt the request of a few posters who want to start afresh, welcome to the IXC charting thread going forward!If you're a poster who is inclined to track TA,. Folks say we are pioneers of craft ice cream in Victoria. RDN Raiden Resources secures complete control of lithium at Arrow Project, buys out Arrow Minerals Ltd. Latest Posts. . ASX - Day TradingAs thread states post your questions here and let’s start compiling a list. 79 -0. IXC Price at posting: 45. 63%. Lots of possible reasons for this - but regardless, it points to Tom knowing that there is upside to this current SP. Australia's largest stock trading and investment forum Australia's #1 stock forum Australia's #1 stock forumFound this article a while back although raises some decent points. ASX - By Stock. ASX - Day TradingIf IXC is positioning itself as a takeover target and the trial endpoints allow for it, it would make sense to provide early readouts. 375,000. I think having this out we can discuss on the way. Charts. HotCopper has news, discussion, prices and market data on IONIC RARE EARTHS LIMITED. ASX - Day TradingCreated with Sketch. ASX - By Stock. . Created with Sketch. . ASX - Day Trading. Forums. You’d be surprised the volume that comes in when this happenes, but by that stage you’ll be 100% up whilst the opportunity cost traders will be trying to catch the move up. ASX - Short Term Trading. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical. Australia's largest stock trading and investment forum Australia's #1 stock forumMay 18 (Reuters) - Invex Therapeutics Ltd (IXC) : INVEX THERAPEUTICS SEEKS TRADING HALT PENDING RELEASE ON RESULTS OF ITS PHASE II TRIAL & UNDERTAKING A. Im not expecting anything out of the ordinary apart from the fact thats its overdone and too undervalued at the stage its at. ASX - By Stock. Release Date: 21/11/22 08:18; Summary: First Patient Randomised in IIH EVOLVE Phase III Trial; Price Sensitive: Yes; Download Document 205. . rights. . Andrew Forrest , or his entities have been involved with IXC since inception. . The announcement was certainly a setback but we're not dead in. Discover historical prices for IXC. ASX - Day Tradingis invex releasing 2. It's essentially a cashed up shell company right now it. Consequently, this would result in faster market penetration and an accelerated timeline to peak sales. Latest Posts. $100-200k might be the minimum for the market to take notice. ASX - General. 91%) As of 03:35PM EST. Access the latest research articles and market investment insight for INVEX THERAPEUTICS LTD seamlessly. Below is the broker data for IXC November to. ASX - By Stock. 54am 24/11/2023 ? HotCopper has news, discussion, prices and market data on INCA MINERALS LIMITED. IAMIncome Asset Management to boost bond sales through partnership with Netwealth. Charts. US data averaged $2314 per person in direct medical care, the total average direct cost per IIH admission was 4x that or $9256. ASX - Day TradingTo name a few other biotechs that have gotten belted by the market of the last few months that have had decent bounces such as NOX, NYR and PEB. ASX - By Stock. All IMO IXC Price at posting: 37. . 1. ASX - Day TradingInvex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical. I don't mind a capital return but you have to think that a reverse take over of some sort can happen here and that IXC would have lots of choices. Report to HotCopper and itll be the end of it, cheers. . Charts. Created with Sketch. . Created with Sketch. 1. Invex Therapeutics Ltd. Last updated 10. Anyone buying now can carry to $5 and then sell a few prior to readout as insurance against losing everything in the coin flip. Forex. ASX - By Stock. , page-4. pdfGreat to see initiation of research from MST today, click the link to read the full report or read the first page in post. 20. . Latest Posts. ASX - General. If IXC is positioning itself as a takeover target and the trial endpoints allow for it, it would make sense to provide early readouts. Charts. ASX - General. Invex Granted Type C Meeting with FDA, page-3. @FullMoonFever Another chart request if you are up for it please thanks in advance, page-8. 5¢ Sentiment: Buy Disclosure: Held. 1950. Forums. Invex to Present at Virtual ASX Small and Mid-Cap ConferenceHealth & BiotechMay 24, 2020|Tim BorehamSHAREFrom the bulging file of Nasty Obscure Diseases we present idiopathic intracranial hypertension (IIH), a. Should jump back in Titans, was good having you on board as you know your stuff IXC Price at posting: 57. Invex Receives Approval for Paediatric Plan from the EMA, page-3. My understanding is that NEU went from around $1. pdfGreat to see initiation of research from MST today, click the link to read the full report or read the first page in post. I guess that's why retail performs so poorly on average, so many think they are long term investors but can't hold onto their shares for more. ASX - Short Term Trading. is there any news release, or SP increasing due to only the market showing interestInvex Receives UK Approval to Commence Phase III TrialInvex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical. 7KB AVG: 22/11/2023 1:08 PM : 2023 AVG AGM Addresses and Presentation 35 pages 3. Interested to hear that Scott believes the company didn't have the phase 2 data for the initial meeting with FDA/EMA. ASX - By Stock. ASX - By Stock. 54am 24/11/2023 ? HotCopper has news, discussion, prices and market data on INCA MINERALS LIMITED. Created with Sketch. 38 Biotechnology stocks are valued based on a risk. Given that IXC's Chief Scientific Officer, Alex Sinclair, is the author of IIH treatment guidelines, the introduction of an effective medication to the market would likely lead to a rapid integration of Presendin into treatment protocols. . Market . Results of MeetingFor those curious about the T20 moves over the last 2 months of available data;Underlined = UnchangedGreen = Positive ChangeRed = Negative ChangeDYOR, not. 392 10/12/19 20:43 Post #: 41898691 Share @FullMoonFever Another chart request if you are up for it please thanks in advance IXC Valuation Report MST. Forums. , page-35. , page-5. Proposed listing date: 4 JULY 2019#Created with Sketch. Global Phase 3 Trial of Presendin to Launch in Q4 2021, page-3. Share Would anyone know whether the 28c cash backing strips out all of the options listed in the notice? or is it included and they will fall away on strike dates?wonder if the GLP-1 agonist referred to in this media release. ASX - Day Trading. 5¢ Sentiment: Buy Disclosure: Held Created with Sketch. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical. IXC current EV is close to $0 so again Im not sure what OSL valuation is but I dont think it stacks up as good as IXC and where IXC is at in its timeline. Too many factors to make an educated appraisal of buyout pre-Phase 2 or post Phase 2. ASX - By Stock. Share Appreciate the commentary and post. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical development Company with issued patents and multiple orphan drug designations focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of. Created with Sketch. 6% $DLM 50. ASX - Day Trading It is certainly an interesting case study regarding management strategy; that noted strategy would work during fair or bullish markets as participants are acting rationally (and by sticking to their knitting during Covid Crash the IXC share price bounced back heavily with Phase II results - so perhaps thats what they were thinking would happen. ASX - By Stock. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical development Company with issued patents and multiple orphan drug designations focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving. Forums. Join the HotCopper ASX share market forum today for free. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical development Company with issued patents and multiple orphan drug designations focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of. I bought the chart from base lows looking for a trade. Charts. . Strong buy side, sell side still very thin. Of course IXC isnt the stock market but its coincidental that selling has stopped around this 17 cents mark which aligns with the old trend line from back in the days. Join the HotCopper ASX share market forum today for free. 9 more clinical sites to be rapidly activated in a country with a growing incidence of IIH cases. Created with Sketch. . . ASX - General. , page-4. Yet since market announcement of Phase 2 completion, this. . . Forums. ASX - By Stock. *Close price adjusted for splits. 0. Notice of Annual General Meeting/Proxy FormInvex Receives Written Response from FDA on Type C MeetingNotification of cessation of securities - IXC. ASX - General. ASX - Day TradingCreated with Sketch. Advertise on HotCopper. Created with Sketch. Not sure what software this is but is there a way you can send the document itself, is a tad tough to read it with the photo you sent, if not all good, page-4. ASX - Short Term Trading. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical. Invex Receives Approval for Paediatric Plan from the EMA, page-3. Although, IXC is trading about 3-4x lower than what I expect it to be for current stage ($100M-$125M MC aka $75-100M EV) Hi All, Having scrolled through the IXC forum for 18-24 months now, I have seen quite literally 200+ posts of charts discussing the stock price, and only. , page-4. , page-5. ASX - Day Trading. IXC Valuation Report MST. Created with Sketch. . But since the cash holding is double the market cap, there most likely more upside than down side. . Target our investor community with our suite of Hotcopper Advertising opportunities. . Very tempted to buy them back today at 19c. With regard to costs, I'm encouraged by this statement in the release: Overall, the changes are expected to be cash neutral with respect to the original IIH EVOLVE trial costing, with recruitment anticipated to materially accelerate due to an expected significant reduction in pre-screen and screen failures. , page-75. . Slow and steady with IXC. ASX - General. 10 cents a week and we will be at $2 plus in no time. pdfGreat to see initiation of research from MST today, click the link to read the full report or read the first page in post. 5¢ Sentiment: Buy Disclosure: HeldAt the request of a few posters who want to start afresh, welcome to the IXC charting thread going forward!If you're a poster who is inclined to track TA,. IXC on the other hand with nearer catalysts has already done its basing cycle Of course different stock different TAMS etc etc, probably why IMU is worth 640 mill MC and IXC 28 mill MC But again its why IXC is offering so much more in terms of value atm plus risk v reward All IMO of course, but yeh maybe some IMU investors pop across. . Market . 147,415. June 15 (Reuters) - Invex Therapeutics Ltd (IXC) : INVEX RECEIVES WRITTEN RESPONSE FROM FDA ON TYPE C MEETING ON PHASE III CLINICAL TRIAL DESIGN FOR. com. Notice of Quarterly Investor Call. Can't see how this doesn't push up soon, page-508. Created with Sketch. Interexchange carriers (IXCs) own or share the various high-bandwidth, fiber-optic trunk lines that cross the country and provide high-speed switched digital services for voice, data, and video communication. The Calmer Co (ASX:CCO) breaks new ground in Australian Retail with Kava shots to launch in Coles from January 2024Hi guys, after discussion with Tom I have kind of mapped out the timeline to what is to be achieved. . Just unfortunate to hit the black swan so badly here, both the. The IXC stock may trade low due to this wider macroeconomic issues, but the business itself is top 5% to its peers merely from the fact of having no future funding requirements and that if the trial is a success having close to immediate revenues and default alive status via Peptron manufacturing contract fulfilling demand on potential FDA. 59 before first real pull back (those lines will be used in the future, they always set it up for that reason, being $3. Toubani Resources is an exploration and development company with a focus on developing a gold platform in West Africa. 59). Although, IXC is trading about 3-4x lower than what I expect it to be. Charts. 7% #asx #ausbiz 23 Jun 2023 06:06:11Not been following IXC but it seems that this Orphan Drug Designation for TBI now have $0 value due to the other Phase III trial update and the company is. Anyone had a look at this or put an application in for some stock in the IPO?, page-2. . For IXC I see the risk in one indication, comparatively lower TAM than others and different formulation for a week duration while phase II used daily. , page-3. Report Created with Sketch. .